Madrigal Pharmaceuticals
MDGL
223 hedge funds and large institutions have $3.36B invested in Madrigal Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 76 increasing their positions, 55 reducing their positions, and 34 closing their positions.
158% more call options, than puts
Call options by funds: $385M | Put options by funds: $149M
106% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 34
38% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 55
19% more funds holding
Funds holding: 188 → 223 (+35)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
1.43% less ownership
Funds ownership: 77.88% → 76.45% (-1.4%)
13% less capital invested
Capital invested by funds: $3.86B → $3.36B (-$498M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$148M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$107M |
| 3 |
Janus Henderson Group
London,
|
+$52.6M |
| 4 |
Renaissance Technologies
New York
|
+$46.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$202M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$125M |
| 3 |
LC
L1 Capital
Melbourne VIC 3000,
Australia
|
-$38.7M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$37.6M |
| 5 |
D.E. Shaw & Co
New York
|
-$35M |
MDGL Hedge Fund Activity: Q1 2023 in Review
223 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2023, worth a combined $3.36B — down 13% from $3.86B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new MDGL positions and 34 closed out — a net gain of 36 holders — while 76 added to existing stakes and 55 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $148M. The largest seller was State Street, cutting an estimated $202M.
- 223 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2023, up from 188 in Q4 2022.
- Funds reported $3.36B of Madrigal Pharmaceuticals stock for Q1 2023, down 13% quarter-over-quarter.
- 70 funds opened new Madrigal Pharmaceuticals positions in Q1 2023 and 34 closed out, a net change of +36 holders.
- The largest Madrigal Pharmaceuticals buyer in Q1 2023 was Marshall Wace, an estimated $148M added.
- The largest Madrigal Pharmaceuticals seller in Q1 2023 was State Street, an estimated $202M sold.
Based on aggregated 13F filings for Q1 2023.